ES2796476T3 - Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona - Google Patents

Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona Download PDF

Info

Publication number
ES2796476T3
ES2796476T3 ES17711562T ES17711562T ES2796476T3 ES 2796476 T3 ES2796476 T3 ES 2796476T3 ES 17711562 T ES17711562 T ES 17711562T ES 17711562 T ES17711562 T ES 17711562T ES 2796476 T3 ES2796476 T3 ES 2796476T3
Authority
ES
Spain
Prior art keywords
acid
crystalline form
sodium
luminol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17711562T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Martin
Josef Breu
Juliane Fleissner
Wolfgang Brysch
Wegerer Jörg Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metriopharm AG
Original Assignee
Metriopharm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm AG filed Critical Metriopharm AG
Application granted granted Critical
Publication of ES2796476T3 publication Critical patent/ES2796476T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES17711562T 2016-02-16 2017-02-15 Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona Active ES2796476T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16000380 2016-02-16
PCT/EP2017/000209 WO2017140422A1 (en) 2016-02-16 2017-02-15 Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

Publications (1)

Publication Number Publication Date
ES2796476T3 true ES2796476T3 (es) 2020-11-27

Family

ID=55361317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17711562T Active ES2796476T3 (es) 2016-02-16 2017-02-15 Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona

Country Status (8)

Country Link
US (1) US11203575B2 (enExample)
EP (1) EP3416952B1 (enExample)
JP (1) JP6949856B2 (enExample)
KR (1) KR102535959B1 (enExample)
CN (1) CN109071461B (enExample)
CA (1) CA3011766C (enExample)
ES (1) ES2796476T3 (enExample)
WO (1) WO2017140422A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3870175B1 (en) * 2018-10-26 2024-08-28 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
EP3858328A1 (en) * 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
PL4125802T3 (pl) * 2020-03-25 2026-03-23 Metriopharm Ag 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc
AU2021288757B2 (en) * 2020-06-10 2026-01-08 Metriopharm Ag Compound for the treatment of coronaviral infections
KR20230116786A (ko) 2020-12-01 2023-08-04 리버스피에이에이치 엘엘씨 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물
US20240075029A1 (en) * 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
EP4460309B1 (en) * 2022-01-07 2026-08-19 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743541A (en) * 1985-07-17 1988-05-10 Mast Immunosystems, Inc. Luminescent substrate preparation and its use in specific binding assays
FR2839155B1 (fr) * 2002-04-25 2005-02-04 Roc Imp Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang
BRPI0307864B1 (pt) * 2003-11-25 2016-01-12 Univ Rio De Janeiro processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos
CN100390152C (zh) * 2006-03-23 2008-05-28 潘健 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
PT2542535E (pt) * 2010-03-01 2014-08-25 Metriopharm Ag Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
WO2011123776A2 (en) * 2010-04-01 2011-10-06 Guthery B Eugene Method for detecting occult blood
US20110246075A1 (en) * 2010-04-01 2011-10-06 Banik Niranjan C Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure

Also Published As

Publication number Publication date
EP3416952B1 (en) 2020-04-08
EP3416952A1 (en) 2018-12-26
US20200369623A1 (en) 2020-11-26
JP6949856B2 (ja) 2021-10-13
JP2019504865A (ja) 2019-02-21
CA3011766C (en) 2023-08-01
CN109071461A (zh) 2018-12-21
CN109071461B (zh) 2022-06-21
US11203575B2 (en) 2021-12-21
CA3011766A1 (en) 2017-08-24
KR20180107278A (ko) 2018-10-01
KR102535959B1 (ko) 2023-05-23
WO2017140422A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
ES2797299T3 (es) Forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona
US11203575B2 (en) Methhod for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
ES2880500T3 (es) Composiciones farmacéuticas que contienen nitrito de sodio
ES3029560T3 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione as glucocorticoid-sparing agent
CN111295369B (zh) 碳酸加合物
WO2017202496A1 (en) Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the ligaments of the joints, articular capsules and bursae
KR102687603B1 (ko) 공결정, 이의 제조방법 및 공결정을 함유하는 의약
JP7807378B2 (ja) 稀な慢性炎症性肺疾患の治療における5-アミノ-2,3-ジヒドロ-1,4-フタラジンジオンの使用
EP2815743A1 (en) Ceftibuten formulations
HK40001510B (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001510A (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001511A (en) Crystalline form of 5-amino-2,3-dihydrophtalazine-1,4-dione